重大公告
Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study by Ministry of Health of the Russian Federation
Date of occurrence of the event: Apr 12, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …
Announcement for the company to issue ordinary shares through rights offering
Date of the resolution by the board of directors or decision by the Company: Apr 09, 2019 Number of shares issued: 15,000,000 shares Par Value …
Announcement of capital change registration for the treasury share retirement
Date of the Competent Authority’s approval of the capital reduction: Mar 26, 2019 Date of completion of capital amendment registration: Mar 26, 2019 Effect on …
The board of directors have resolved not to distribute dividends for 2018
Date of the board of directors resolution: Mar 8, 2019 Appropriations of earnings in cash dividends to shareholders (NT$ per share): 0 Cash dividends distributed …
The Board of Directors resolved to hold 2019 Annual General Meeting
Date of the board of directors resolution: Mar 8, 2019 Date for convening the shareholders’ meeting: Jun 27, 2019 Location for convening the shareholders’ meeting: …